Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has announced a new securities purchase plan, offering up to 44,444,444 ordinary fully paid shares alongside equal numbers of quoted options expiring in April 2027 and April 2029 at specified exercise prices. The offer, with a record date of 10 March 2026, is scheduled to close on 15 April 2026 and have securities issued on 21 April 2026, reinforcing the company’s capital position and providing existing shareholders a structured avenue to participate in its future growth.
Under the plan, Imugene will seek quotation of all new securities on the ASX, including the newly created classes of quoted options, in line with the exchange’s listing rules and disclosure framework. The proposed capital raising underscores the company’s reliance on equity markets to support its operations and may influence its liquidity profile and shareholder base, as investors weigh the dilutive impact against the potential upside from expanded funding capacity.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.21 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-listed biotechnology company focused on developing novel immunotherapies, with its ordinary shares traded on the ASX under the code IMU. The company operates in the life sciences sector, using capital markets to fund ongoing research, clinical development, and commercialisation activities in its pipeline.
Average Trading Volume: 1,405,648
Technical Sentiment Signal: Sell
Current Market Cap: A$73.95M
For a thorough assessment of IMU stock, go to TipRanks’ Stock Analysis page.